dohh-1 Antibody

What is DOHH and what cellular functions does it regulate?

Deoxyhypusine hydroxylase (DOHH) is an enzyme that catalyzes the second step in the post-translational synthesis of hypusine [Nε-(4-amino-2-hydroxybutyl)lysine] in the eukaryotic initiation factor 5A (eIF5A) . This 33 kDa protein plays crucial roles in multiple cellular processes including proliferation, differentiation, and apoptosis . DOHH has been implicated in several important biological pathways relevant to human diseases, including cancer growth, malarial drug resistance, and HIV-1 replication . Recent research has established that the DOHH/eIF5A signaling pathway mediates nerve growth factor effects, suggesting its importance in neuronal development and function .

What applications are DOHH-1 antibodies validated for?

DOHH-1 antibodies have been validated for multiple research applications that enable comprehensive investigation of this protein:

• Western Blot (WB): For detecting DOHH protein expression in cell and tissue lysates with high sensitivity

• Immunofluorescence (IF)/Immunocytochemistry (ICC): For visualizing subcellular localization of DOHH

• ELISA: For quantitative detection of DOHH in various sample types

These validated applications allow researchers to investigate DOHH expression patterns, subcellular distribution, and potential interactions with other proteins in the hypusination pathway.

What is the reactivity profile of DOHH-1 antibody?

DOHH antibodies show cross-reactivity with multiple species and cell types, making them versatile tools for comparative studies:

This broad reactivity profile makes DOHH-1 antibody suitable for studies across various experimental models and cell lines .

What dilutions are recommended for different applications?

Optimal antibody dilution is critical for achieving specific signal with minimal background. For DOHH-1 antibody, the recommended dilutions vary by application:

It's important to note that optimal dilutions may be sample-dependent, and researchers should titrate the antibody in their specific experimental systems to obtain optimal results .

How should I optimize Western blot conditions for DOHH-1 antibody?

Optimizing Western blot protocols for DOHH-1 antibody requires careful consideration of several experimental parameters:

Sample Preparation:

• Use RIPA or NP-40 buffer supplemented with protease inhibitors for efficient extraction

• Load 20-50 μg of total protein per lane for optimal detection

• Include positive control samples such as LNCaP, HeLa, or HEK-293 cell lysates

Gel Electrophoresis and Transfer:

• Use 10-12% SDS-PAGE gels for optimal resolution around the 30-35 kDa range where DOHH is detected

• The calculated molecular weight of DOHH is 33 kDa, but the observed molecular weight typically falls between 30-35 kDa

• Ensure complete protein transfer to PVDF or nitrocellulose membranes

Antibody Incubation:

• Begin with a 1:10000 dilution and adjust based on signal intensity

• Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• The high dilution range (up to 1:50000) suggests high antibody affinity and specificity

Detection and Analysis:

• Use appropriate secondary antibodies matched to the mouse IgG1 isotype of the primary antibody

• Implement stringent washing steps (4-5 washes, 5 minutes each) to minimize background

• Consider chemiluminescence detection for high sensitivity applications

What controls are essential when using DOHH-1 antibody in immunofluorescence?

Rigorous controls are critical for valid immunofluorescence experiments with DOHH-1 antibody:

Essential Positive Controls:

• Include LNCaP cells, which have been validated to show positive staining with DOHH-1 antibody

• Compare staining patterns with published literature on DOHH subcellular localization

Negative Controls:

• Omit primary antibody (secondary-only control) to assess non-specific binding

• Use isotype control (mouse IgG1) at equivalent concentration to evaluate background

• If available, include DOHH-knockdown cells to confirm staining specificity

Technical Controls:

• Include nuclear counterstain (DAPI or Hoechst) to provide cellular context

• Consider co-staining with markers of subcellular compartments to verify localization patterns

• Use consistent image acquisition settings across all experimental conditions

Optimization Parameters:

• Test different fixation methods (4% paraformaldehyde for 10-15 minutes works well for many applications)

• Optimize permeabilization conditions (0.1-0.5% Triton X-100 for 5-10 minutes)

• Titrate antibody within the recommended 1:400-1:1600 dilution range

How can DOHH-1 antibody be used to study the hypusination pathway?

Investigating the DOHH-eIF5A hypusination pathway requires integrating multiple experimental approaches:

Two-dimensional Gel Electrophoresis:

• This technique can distinguish between non-modified, deoxyhypusinated, and fully hypusinated eIF5A

• In cells with DOHH deficiency, accumulation of deoxyhypusine-containing eIF5A [eIF5A(Dhp)] and reduction in hypusinated eIF5A can be observed

• Combine with Western blotting using DOHH-1 antibody to correlate DOHH levels with eIF5A modification states

Co-immunoprecipitation Studies:

• Use DOHH-1 antibody to pull down DOHH protein complexes

• Analyze co-precipitated proteins for the presence of eIF5A and other pathway components

• This approach can identify protein-protein interactions within the hypusination pathway

Immunofluorescence Co-localization:

• Perform dual immunofluorescence with DOHH-1 antibody and anti-eIF5A antibodies

• Analyze spatial relationships between enzyme and substrate

• Quantify co-localization coefficients in different cellular compartments

Genetic Manipulation Coupled with Antibody Detection:

• In DOHH knockdown/knockout models, use the antibody to confirm reduced DOHH protein levels

• Correlate changes in DOHH levels with alterations in eIF5A hypusination and downstream cellular effects

• This approach establishes causality between DOHH activity and observed phenotypes

What biochemical defects can be detected using DOHH-1 antibody in cells with DOHH variants?

DOHH-1 antibody can be instrumental in characterizing biochemical abnormalities associated with DOHH gene variants:

Detection of Altered Protein Expression:

• Western blotting with DOHH-1 antibody can reveal reduced DOHH protein levels in cells harboring bi-allelic DOHH variants

• Quantitative analysis can establish correlations between variant type and protein expression levels

Analysis of eIF5A Hypusination Defects:

• Two-dimensional gel analyses of patient-derived fibroblasts can reveal accumulation of deoxyhypusine-containing eIF5A and reduction in hypusinated eIF5A

• DOHH-1 antibody can be used to confirm DOHH deficiency in these cells

Subcellular Localization Studies:

• Immunofluorescence with DOHH-1 antibody can detect potential mislocalization of mutant DOHH proteins

• Co-staining with organelle markers can identify aberrant localization patterns

Functional Rescue Experiments:

• After reintroducing wild-type DOHH in deficient cells, the antibody can confirm successful expression

• This approach enables correlation between restored DOHH expression and normalization of eIF5A hypusination

How is DOHH implicated in neurodevelopmental disorders?

Recent research has established a critical link between DOHH dysfunction and neurodevelopmental disorders:

Genetic Evidence:

• Bi-allelic variants in the DOHH gene (MIM: 611262) have been identified in individuals with neurodevelopmental disorders

• These variants were discovered through exome sequencing performed at multiple research centers

• The inheritance pattern is recessive, as parents carrying heterozygous variants did not exhibit neurodevelopmental features

Clinical Phenotypes:

• Affected individuals display consistent features including:

  • Global developmental delay

  • Intellectual disability

  • Facial dysmorphism

  • Microcephaly

Biochemical Mechanism:

• Two-dimensional gel analyses of patient-derived fibroblasts revealed:

  • Accumulation of deoxyhypusine-containing eIF5A [eIF5A(Dhp)]

  • Reduction in fully hypusinated eIF5A

  • These findings provide direct biochemical evidence for DOHH deficiency

Experimental Models:

• DOHH-1 antibody can be used to validate DOHH expression levels in:

  • Patient-derived fibroblasts

  • Induced pluripotent stem cells (iPSCs)

  • Neuronal differentiation models

  • Animal models of DOHH deficiency

What experimental approaches can characterize DOHH's role in cellular proliferation?

DOHH has been implicated in cellular proliferation, and several methodological approaches utilizing DOHH-1 antibody can elucidate its specific roles:

Proliferation Assays with DOHH Modulation:

• Manipulate DOHH levels through knockdown or overexpression

• Use DOHH-1 antibody to confirm successful modulation by Western blot

• Correlate DOHH protein levels with proliferation metrics (cell counting, MTT assay, BrdU incorporation)

Cell Cycle Analysis:

• Synchronize cells at different cell cycle phases

• Analyze DOHH expression and localization throughout the cell cycle using DOHH-1 antibody

• Perform dual staining with cell cycle markers to correlate DOHH expression with specific phases

Cancer Cell Models:

• Compare DOHH expression levels across cancer cell lines with different proliferation rates

• Analyze the impact of DOHH inhibition on cancer cell growth

• The established role of DOHH in cancer growth makes this a particularly relevant research direction

Molecular Pathway Analysis:

• Investigate the relationship between DOHH/eIF5A pathway and known proliferation signaling cascades

• Use DOHH-1 antibody in combination with phospho-specific antibodies for proliferation pathway components

• Perform immunoprecipitation studies to identify novel interaction partners involved in proliferation regulation

How can DOHH-1 antibody be used to investigate the DOHH/eIF5A pathway in disease models?

The DOHH/eIF5A pathway has been implicated in various diseases, and DOHH-1 antibody provides valuable tools for mechanistic investigations:

Neurodevelopmental Models:

• Use DOHH-1 antibody to assess DOHH expression in neuronal differentiation models

• Compare DOHH localization between healthy and disease model neurons

• Correlate DOHH expression with neurodevelopmental markers

Cancer Research Applications:

• Analyze DOHH expression across cancer types and stages

• Investigate correlation between DOHH levels and cancer aggressiveness

• Study the effects of DOHH inhibition on cancer cell survival and proliferation

Infectious Disease Models:

• Examine DOHH's role in HIV-1 replication, as mentioned in the literature

• Investigate changes in DOHH expression during viral infection

• Assess the effects of DOHH inhibition on viral replication cycles

Pharmacological Studies:

• Use DOHH-1 antibody to monitor protein levels after treatment with DOHH inhibitors

• Validate target engagement in drug discovery pipelines

• Assess on-target versus off-target effects of potential therapeutic compounds

What are the critical storage and handling requirements for DOHH-1 antibody?

Proper storage and handling are essential for maintaining antibody performance:

Storage Conditions:

• Store at -20°C for long-term stability

• The antibody is supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• For smaller aliquots (20μl sizes containing 0.1% BSA), aliquoting is unnecessary for -20°C storage

Freeze-Thaw Considerations:

• Minimize freeze-thaw cycles for larger volumes

• Prepare working aliquots for frequent use applications

• Allow antibody to equilibrate to room temperature before opening the vial

Handling Precautions:

• Avoid contamination by using clean pipette tips

• Work with antibody solutions on ice when preparing dilutions

• Centrifuge briefly before opening to collect solution at the bottom of the vial

How can I validate DOHH-1 antibody performance in my experimental system?

Thorough validation ensures reliable results across different experimental systems:

Specificity Assessment:

• Perform Western blot using positive control lysates (LNCaP, HeLa, HEK-293 cells)

• Confirm the expected molecular weight (30-35 kDa)

• If available, include DOHH-knockdown or knockout samples as negative controls

Sensitivity Testing:

• Perform serial dilutions of sample and antibody to determine detection limits

• Compare signal-to-noise ratios across different antibody concentrations

• Identify optimal conditions that balance specific signal and background

Cross-Reactivity Evaluation:

• Test reactivity across different species if working with non-human models

• Confirmed reactivity includes human, mouse, and rat samples

• Perform peptide competition assays to confirm epitope specificity

Application-Specific Validation:

• For immunofluorescence, compare staining patterns with published literature

• For co-immunoprecipitation, verify pull-down efficiency and specificity

• Document validation data systematically for reproducible research practices